Emmaus Life Sciences, Inc.
- EMMA · OTC
- Pharmaceutical Preparations
- Torrance, CA
- 33 employees
- CIK 0000822370
Updated from SEC filings through
Top things to know
Executives
- Willis C. Lee CEO 4, 2026-09-02
- Charles Stark Chief Science Officer & Executive Vice President of Clinical Development and Medical Affairs, Clinical, Regulatory 10-K, 2026-03-31
- Charles Stark, Pharm.D. Chief Science Officer & EVP of Clinical Development and Medical Affairs 10-K, 2026-03-31
- Hiroko Huynh Chief Accounting Officer 10-K, 2026-03-31
Emmaus Life Sciences, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Torrance, CA. It trades as EMMA on OTC. Revenue was $12.5M in the fiscal year ending December 31, 2025, -25.2% from the year before. It reported about 33 employees. Willis C. Lee is CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $12.5M 10-K, 2026-03-31 | $16.7M 10-K, 2026-03-31 | $29.6M 10-K, 2025-04-14 | $18.4M 10-K, 2024-07-03 | $20.6M 10-K, 2023-03-31 |
| Operating income | $231K 10-K, 2026-03-31 | -$1.9M 10-K, 2026-03-31 | $3.5M 10-K, 2025-04-14 | -$6.6M 10-K, 2024-07-03 | -$6.1M 10-K, 2023-03-31 |
| SG&A | $11.1M 10-K, 2026-03-31 | $16.7M 10-K, 2026-03-31 | $23.5M 10-K, 2025-04-14 | $20.7M 10-K, 2024-07-03 | $19.3M 10-K, 2023-03-31 |
| Net income | -$7.5M 10-K, 2026-03-31 | -$6.5M 10-K, 2026-03-31 | -$3.7M 10-K, 2025-04-14 | -$10.6M 10-K, 2024-07-03 | -$15.9M 10-K, 2023-03-31 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Willis C. Lee CEO at Emmaus Life Sciences / Emmaus Medical | CEO | 4, 2026-09-02 |
| Charles Stark | Chief Science Officer & Executive Vice President of Clinical Development and Medical Affairs, Clinical, Regulatory | 10-K, 2026-03-31 |
| Charles Stark, Pharm.D. | Chief Science Officer & EVP of Clinical Development and Medical Affairs | 10-K, 2026-03-31 |
| Hiroko Huynh | Chief Accounting Officer | 10-K, 2026-03-31 |
| Jon Kuwahara | Director | 10-K, 2026-03-31 |
| Wei Peu Zen | Director | 10-K, 2026-03-31 |
What Emmaus Life Sciences, Inc. does
We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease (“SCD”) in adult and pediatric patients five years of age and older.E, Qatar, Kuwait, Bahrain and Oman. Our a pplication for marketing authorization in the Kingdom of Saudi Arabia, or KSA, is pending.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 70.2 million (as of August 11, 2026) | 10-Q, August 14, 2026 |
|---|---|---|
| Public float | $582K (as of June 30, 2025) | 10-K, March 31, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 14, 2026 |
| Latest proxy statement | Meeting December 8, 2022 (filed October 31, 2022) | DEF 14A, October 31, 2022 |
| Auditor | CBIZ CPAs P.C. (Costa Mesa, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 31, 2026 | Willis C. Lee CEO | Buy | 530,767 | $18K | Form 4, September 2, 2026 |
Recent 8-K events
- 8-K filed 2026-08-14
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-15
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-17
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-04-14
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-31
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-04
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2025-12-31
- Item 1.01 Entry into a material definitive agreement
- Item 8.01 Other events
- 8-K filed 2025-12-22
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2025-12-19
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-11-14
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Emmaus Life Sciences, Inc.
- What does Emmaus Life Sciences, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease (“SCD”) in adult and pediatric patients five years of age and older.E, Qatar, Kuwait, Bahrain and Oman. Our a pplication for marketing authorization in the Kingdom of Saudi Arabia, or KSA, is pending."
- What is Emmaus Life Sciences, Inc.'s revenue?
- $12.5M for the fiscal year ending December 31, 2025, from its 10-K filed March 31, 2026.
- Is Emmaus Life Sciences, Inc. profitable?
- Emmaus Life Sciences, Inc. reported net income of -$7.5M for the fiscal year ending December 31, 2025.
- How many employees does Emmaus Life Sciences, Inc. have?
- About 33 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Emmaus Life Sciences, Inc.?
- Willis C. Lee, CEO, as named in a 4 filed September 2, 2026.
- Where is Emmaus Life Sciences, Inc. headquartered?
- Torrance, CA.
- What is Emmaus Life Sciences, Inc.'s stock ticker?
- EMMA on OTC.
- What industry is Emmaus Life Sciences, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Emmaus Life Sciences, Inc.'s website?
- emmausmedical.com. Investor relations: https://ir.emmausmedical.com.
- When does Emmaus Life Sciences, Inc. report earnings next?
- November 14, 2026. Source: estimate_10q_cadence.
- Is Emmaus Life Sciences, Inc. a public company?
- Yes. Emmaus Life Sciences, Inc. files with the SEC under CIK 0000822370 and trades as EMMA.
- Who audits Emmaus Life Sciences, Inc.?
- CBIZ CPAs P.C., Costa Mesa, California, as named in its latest annual report (10-K).
- How many shares of Emmaus Life Sciences, Inc. are outstanding?
- 70.2 million shares as of August 11, 2026, from its 10-Q filed August 14, 2026.
- What is Emmaus Life Sciences, Inc.'s public float?
- $582K as of June 30, 2025, as reported on the cover of its 10-K filed March 31, 2026.
- How many business segments does Emmaus Life Sciences, Inc. report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 14, 2026.
- When is Emmaus Life Sciences, Inc.'s annual shareholder meeting?
- December 8, 2022, per its proxy statement (DEF 14A) filed October 31, 2022.
- Have Emmaus Life Sciences, Inc. insiders traded stock recently?
- Since August 31, 2026, officers and directors reported 0 open-market sales and 1 purchase worth about $18K on Forms 4 and 5. The most recent: Willis C. Lee (CEO) bought 530,767 shares on August 31, 2026.